Adastra Labs Ltd. (OTCPK:XTXXF) (CSE:XTRX) (FRA:D2EP) provided clarification regarding its receipt of Health Canada approval for the amendment to include cocaine under its controlled substances license.
The company received its Controlled Substances License ("dealer's license") on August 24, 2022 and an amendment on February 17, 2023. The company's wholly-owned subsidiary Adastra Labs Inc. is licensed to conduct the following regulated activities: possession, production, assembling, sale/provision and sending, transportation and delivery with coca leaf, cocaine, and psilocybin. Adastra Labs may only produce 1,000 grams of psilocybin and 250 grams of cocaine …